Latest Healthcare Innovation News

BlinkLab Limited has raised A$7.66 million through a well-supported placement to accelerate FDA regulatory trials for its autism and ADHD diagnostic platforms, leveraging its innovative smartphone-based technology.

Recce Pharmaceuticals reports strong Phase II clinical trial results for its topical anti-infective R327G, achieving a 93% efficacy rate in treating ABSSSI, alongside a significant capital raise to fund upcoming Phase III trials.

Anatara Lifesciences reports mixed results from its Phase II GaRP-IBS trial, missing the primary efficacy target but showing significant improvements in anxiety and patient-reported relief, while advancing its anti-obesity pre-clinical program.

InteliCare Holdings has secured a new commercial trial with mecwacare and advanced deployments at Hardi Aged Care sites, underpinning growth in its AI-driven aged care platform amid regulatory changes.

Optiscan Imaging Ltd has revealed its next-generation InForm™ pathology imaging device and strengthened its executive team, while reporting a robust cash position supported by a $1.775 million R&D tax refund for the quarter ended 31 March 2025.

EMVision Medical Devices has commenced the pivotal clinical trial for its emu™ bedside brain scanner aimed at FDA clearance, while advancing its First Responder device through successful aeromedical testing and ethics approvals. The company maintains strong cash reserves of $12.58 million to support ongoing innovation and clinical activities.

InteliCare Holdings has secured a binding agreement to trial its AI-driven platform at mecwacare’s Trescowthick Centre, marking a significant step in its commercialisation strategy within Victoria’s aged care sector.

LTR Pharma reports strong Q1 2025 progress with FDA pre-IND meeting success, scientific acclaim for SPONTAN’s rapid absorption, and strategic launch of ROXUS to fast-track US market entry.

Talius Group reported a solid March quarter with rising revenue, a strategic partnership with Lifestyle SA, and the rollout of its proprietary RTLS software, signaling strong momentum in aged care technology.

Vitrafy Life Sciences reported strong Q3 FY2025 progress, including a successful US Army blood platelet study, a $4.8 million government grant, and strategic US market expansion.

Osteopore Limited has drawn down A$2 million from the first tranche of its redeemable convertible notes, using the proceeds to repay existing loans and support ongoing business activities.

Emyria reports sustained and statistically significant improvements in PTSD symptoms and quality of life three months after MDMA-assisted therapy, signaling a potential breakthrough for treatment-resistant patients.